Immunosuppressive Switch to Sirolimus in Renal Dysfunction After Liver Transplantation

Transplantation Proceedings

Volumn 41, Issue 4, 2009, Pages 1297-1299

  Di Benedetto, F ^a   Di Sandro, S ^a   De Ruvo, N ^a   Montalti, R ^a   Guerrini, G P ^a   Ballarin, R ^a   Spaggiari, M ^a   Mimmo, A ^a   D'Amico, G ^a   Cautero, N ^a   Iemmolo, R M ^a   Gerunda, G E ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; OMEGA 3 FATTY ACID; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; UREA; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM HEMORRHAGE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUTH ULCER; NEPHROTOXICITY; ORTHOTOPIC TRANSPLANTATION; PANCYTOPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; KIDNEY; PATHOPHYSIOLOGY;

GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; SIROLIMUS;

EID: 65549113784     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.03.018     Document Type: Article

References (10)

1. Olyaei A.J., de Mattos A.M., and Bennett W.M. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7 (2001) 384
2. Flechner S.M., Kobashigawa J., and Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22 (2008) 1
3. Wiesner R., Klintmalm G., McDiarmid S., and Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am J Transplant 2 (2002) 464
4. Flanagan W.M., and Crabtree G.R. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. Ann NY Acad Sci 696 (1993) 31
5. Montalbano M., Neff G.W., Yamashiki N., et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78 (2004) 264
6. Yang Y.J., Chen D.Z., Li L.X., et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. Transplant Proc 40 (2008) 1541
7. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 3 suppl (2003) 7S
8. Levey A.S., Coresh J., Greene T., et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007) 766
9. Di Benedetto F., Di Sandro S., De Ruvo N., et al. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction owing to calcineurin inhibitors. J Clin Gastroenterol (2008) [Epub ahead of print]
10. Seaberg E.C., Belle S.H., Beringer K.C., et al. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl (1998) 17